1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P4907
    RGD Negative Control
    Control 99.91%
    RGD Negative Control is the negative control of RGD (HY-P0278).
    RGD Negative Control
  • HY-P6010A
    αvβ6-BP TFA
    98.91%
    αvβ6-BP TFA is a selective αvβ6 binding peptide, and can be used for research of molecular imaging.
    αvβ6-BP TFA
  • HY-B0686B
    Eptifibatide acetate
    Inhibitor
    Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
    Eptifibatide acetate
  • HY-P10038A
    mP6 TFA
    Inhibitor 98.48%
    mP6 (Myr-FEEERA-OH) TFA is a myristoylated peptide. mP6 TFA inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. mP6 TFA can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells.
    mP6 TFA
  • HY-P99184
    Abrilumab
    98.35%
    Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD).
    Abrilumab
  • HY-P99127
    Anti-Mouse CD54 Antibody (YN1/1.7.4)
    Inhibitor
    Anti-Mouse CD54 Antibody (YN1/1.7.4) is an anti-mouse CD54 IgG2b antibody inhibitor derived from host Rat. Anti-Mouse CD54 Antibody (YN1/1.7.4) can neutralize CD54 also known as Intercellular Adhesion Molecule-1 (ICAM-1). Anti-Mouse CD54 Antibody (YN1/1.7.4) can be used for the research of inflammation.
    Anti-Mouse CD54 Antibody (YN1/1.7.4)
  • HY-P990552A
    huATN-658
    Antagonist
    huATN-658 (MNPR-101) is a humanized monoclonal antibody inhibitor targeting urokinase-type plasminogen activator receptor (uPAR). huATN-658 blocks the interaction between uPAR and integrins, inhibiting the proliferation, invasion and migration of tumor cells. huATN-658 is promising for research of breast cancer (especially triple-negative breast cancer).
    huATN-658
  • HY-111413
    c(phg-isoDGR-(NMe)k)
    c(phg-isoDGR-(NMe)k) is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM.
    c(phg-isoDGR-(NMe)k)
  • HY-145728
    Alicaforsen
    Inhibitor
    Alicaforsen is a 20-base antisense oligonucleotide inhibiting ICAM-1 production, which is an important adhesion molecule involved in leukocyte migration and trafficking to the site of inflammation.
    Alicaforsen
  • HY-18668
    Integrin antagonist 27
    Antagonist ≥98.0%
    Integrin antagonist 27 (Compound 27) is a small molecule integrin αvβ3 antagonist with an affinity of 18 nM. Integrin antagonist 27 can be combined with Paclitaxel (HY-B0015) to selectively target αvβ3-positive metastatic cancer cells. Integrin antagonist 27 is used as an anticancer agent.
    Integrin antagonist 27
  • HY-119350
    Zalunfiban
    Zalunfiban (RUC-4) is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban can be used for the research of myocardial infarction (MI).
    Zalunfiban
  • HY-19151
    Fuzapladib
    Inhibitor 98.75%
    Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site.
    Fuzapladib
  • HY-19151A
    Fuzapladib sodium
    Inhibitor 99.61%
    Fuzapladib (IS-741) sodium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib sodium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib sodium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site.
    Fuzapladib sodium
  • HY-P3523
    KGDS
    Activator 99.78%
    KGDS is synthetic peptides, targeting integrin GPIIb-IIIa located on the membrane of human activated platelets. Amino acid sequence: Lys-Gly-Asp-Ser.
    KGDS
  • HY-100573S
    Necrosulfonamide-d4
    Inhibitor 99.26%
    Necrosulfonamide-d4 is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
    Necrosulfonamide-d<sub>4</sub>
  • HY-P990764B
    Sigvotatug (Biotinylated)
    Ligand ≥99.0%
    Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonal antibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Sigvotatug (Biotinylated)
  • HY-P6009A
    Cys-αvβ6-BP TFA
    Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide.
    Cys-αvβ6-BP TFA
  • HY-119926
    13-Hydroxylupanine
    Inhibitor
    13-Hydroxylupanine (Hydroxylupanine) is the typical alkaloid profile of sweet lupins.13-Hydroxylupanine blocks ganglionic transmission, decreases cardiac contractility and contracts uterine smooth muscle.
    13-Hydroxylupanine
  • HY-101720A
    Fradafiban hydrochloride
    Antagonist 99.96%
    Fradafiban (BIBU-52) hydrochloride is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.
    Fradafiban hydrochloride
  • HY-10309
    Sibrafiban
    Antagonist 99.67%
    Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation.
    Sibrafiban
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.